(CercleFinance.com) – Degroof Petercam announced on Tuesday that it had lowered its price target on Poxel from 6.4 to 3.5 euros in order to take into account the dilutive effect linked to the implementation of a new line of financing with Irises.
The Belgian investment house underlines that this target, even reduced, still shows an upside potential of around 400%, which makes it say that the market underestimates the potential of Twymeeg, the main drug candidate of biotech.
The Brussels firm, which maintains its buy recommendation on the stock, stresses that its objective is based up to 90% on its forecasts for Twymeeg, which means that its estimates do not take into account any indications in NASH, adrenomyeloneuropathy (AMN) and autosomal dominant polycystic kidney disease (ADPKD).
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
